Niva Bupa Health Insurance Company Limited has informed the Exchange about Outcome of Board Meeting-Unaudited Financial results for the quarter ended June, 2025.
NIVABUPA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts less than Nifty Smallcap 250 and 4.3 pts less than its General Insurance peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Niva Bupa reported Q1 FY26 results with Gross Premium Written of Rs. 1,63,190 lakhs, up ~11.5% YoY from Rs. 1,46,418 lakhs in Q1 FY25. However, the company swung to a higher loss with Profit After Tax of Rs. (9,144) lakhs versus Rs. (1,882) lakhs loss in the year-ago quarter, translating to a diluted EPS of Rs. (0.50). The Incurred Claim Ratio spiked sharply to 77.86% from 64.14% YoY, pushing the Combined Ratio to 116.97% (vs 106.09%), meaning claims and expenses exceeded premiums. Solvency Ratio improved to 2.86x from 2.39x, supported by fresh IPO funds. The auditor flagged an Emphasis of Matter on the pending IRDAI forbearance for excess Expenses of Management (EOM ratio 35.94% vs 30% regulatory cap for health insurers).
The sharp jump in claim ratio and widening underwriting loss are negatives for near-term profitability, though solvency remains comfortable. Shareholders should watch IRDAI's decision on EOM forbearance and the trajectory of claim costs in coming quarters, while the contingent liabilities from tax and GST matters (over Rs. 10,000 lakhs combined) add some uncertainty.